You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 170 No. 12, June 28, 2010 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Investigation
 •Online Features
 This Article
 •Full text
 •PDF
 •eAppendix
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Bacterial Infections
 •Urinary Tract Disorders
 •Drug Therapy
 •Adverse Effects
 •Drug Therapy, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System

A Population-Based Study

Tony Antoniou, BScPharm, PharmD; Tara Gomes, MHSc; David N. Juurlink, MD, PhD; Mona R. Loutfy, MD, MPH; Richard H. Glazier, MD, MPH; Muhammad M. Mamdani, PharmD, MPH

Arch Intern Med. 2010;170(12):1045-1049.

Background  Trimethoprim therapy can cause hyperkalemia and is often coprescribed with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). The objective of this study was to characterize the risk of hyperkalemia-associated hospitalization in elderly patients who were being treated with trimethoprim-sulfamethoxazole along with either an ACEI or an ARB.

Methods  We conducted a population-based, nested case-control study of a cohort of elderly patients 66 years or older who were residents of Ontario, Canada, and who were receiving continuous therapy with either an ACEI or an ARB. Case patients were those with a hyperkalemia-associated hospitalization within 14 days of receiving a prescription for trimethoprim-sulfamethoxazole, amoxicillin, ciprofloxacin, norfloxacin, or nitrofurantoin. For each case, we identified up to 4 control patients from the same cohort matched for age, sex, and presence or absence of chronic renal disease and diabetes. Odds ratios were determined for the association between hyperkalemia-associated hospitalization and previous antibiotic use.

Results  During the 14-year study period, we identified 4148 admissions involving hyperkalemia, 371 of which occurred within 14 days of antibiotic exposure. Compared with amoxicillin, the use of trimethoprim-sulfamethoxazole was associated with a nearly 7-fold increased risk of hyperkalemia-associated hospitalization (adjusted odds ratio, 6.7; 95% confidence interval, 4.5-10.0). No such risk was found with the use of comparator antibiotics.

Conclusions  Among older patients treated with ACEIs or ARBs, the use of trimethoprim-sulfamethoxazole is associated with a major increase in the risk of hyperkalemia-associated hospitalization relative to other antibiotics. Alternate antibiotic therapy should be considered in these patients when clinically appropriate.


Author Affiliations: Leslie Dan Faculty of Pharmacy (Drs Antoniou and Mamdani and Ms Gomes), Departments of Medicine (Drs Juurlink and Loutfy), Pediatrics (Dr Juurlink), Health Policy, Management, and Evaluation (Drs Juurlink, Loutfy, Glazier, and Mamdani), and Family and Community Medicine (Dr Glazier), and Dalla Lana School of Public Health (Dr Glazier), University of Toronto, Toronto, Ontario, Canada; Department of Family and Community Medicine (Drs Antoniou and Glazier), Centre for Research on Inner City Health (Dr Glazier), and Li Ka Shing Knowledge Institute (Dr Mamdani), St Michael's Hospital,Toronto; Institute for Clinical Evaluative Sciences, Toronto (Ms Gomes and Drs Juurlink, Glazier, and Mamdani); Departments of Medicine, Sunnybrook Health Sciences Centre (Dr Juurlink) and Women's College Hospital (Dr Loutfy), Toronto; and Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia (Dr Mamdani).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Selective Serotonin Reuptake Inhibitors and Pulmonary Arterial Hypertension: A Case-Control Study
Dhalla et al.
Chest 2012;141:348-353.
ABSTRACT | FULL TEXT  

Considerations when prescribing trimethoprim-sulfamethoxazole
Ho and Juurlink
CMAJ 2011;183:1851-1858.
FULL TEXT  

Co-prescription of co-trimoxazole and spironolactone in elderly patients
Wei et al.
BMJ 2011;343:d5656-d5656.
FULL TEXT  

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
Liu et al.
Clinical Infectious Diseases 2011;52:e18-e55.
ABSTRACT | FULL TEXT  

Antibiotic-Induced Hyperkalemia and Renin-Angiotensin-System Inhibitors
JWatch Infect. Diseases 2010;2010:6-6.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2010 American Medical Association. All Rights Reserved.